维普期刊资源整合服务平台（V6.5）

66篇 您的检索式：作者名="Walenga"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Singlet oxygen inhibits agonist-induced P-selectin expression and formation of platelet aggregates显示文摘	Stief TW Jeske WP Walenga J Schultz C Kretschmer V Fareed J	2001	Clin Appl Thromb Hemost2001，7，3：	1
2	Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia显示文摘	Walenga JM Prechel M Jeske WP	2008	Br J Haematol2008，143，1：	1
3	Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro显示文摘	Walenga RW Kester M Coroneos E	1996	Prostaglandins1996，52，5：	1
4	Thrombogenic potential of nonionic contrast media? 显示文摘	FAREED J WALENGA J M SARAVIA G E	1990	Radiology1990，174，2：	1
5	Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide显示文摘	WALENGA J M JESKE W P BARA L	1997	Thromb Res1997，86，：	1
6	Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin induced thrombocytopenia显示文摘	Walenga JM Ahmad S Hoppensteadt D	2002	Thromb Res2002，105，：	1
7	Biochemical and pharmaceutical rationale for the development of a synthetic heparin pentasaccharide显示文摘	WALENGA JM JESKE WP BARA L	1997	Thromb Res1997，86，：	1
8	Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia 显示文摘	Walenga JM Prechel M Hoppensteadt D	2013	Clinical and Applied Thrombosis/Hemostasis2013，19，5：	1
9	Soluble P-selectin in human plasma:effect of anticoagulant matrix and its levels in patients with effect of anticoagulant matrix and its levels in patients with cardiovascular disorders显示文摘	Ahmad S Walenga JM	2000	Clinical & Applied Thromb Hemost2000，6，2：	1
10	Sustained release of tissue factor following thrombosis of lower limb trauma 显示文摘	Walenga JM Kaiser PC Prechel MM	2014	Clin Appl Thromb Hemost2014，20，7：	1
11	Rivaroxaban--an oral, di- rect Factor Xa inhibitor--has potential for the management of pa- tients with heparin-induced thrombocytopenia显示文摘	Walenga JM Prechel M Jeske WP	2008	Br J Haematol2008，143，：	1
12	The role of plateletactivation and therapeutic implication 显示文摘	Haas S Walenga JM Jeske WP etal	1999	Semin Thromb Hemost1999，25，1：	1
13	Mcchanisms of Ve- nous and Arterial Thrombosis in Heparin- induced Throm boeytopenia显示文摘	Walenga JM Jeske WP Messmore HI	2000	Journal of Thrombosis and Thrombolysis2000，10，1：	1
14	Laboratory tests for heparin-induced thrombocytopenia: a multicenter study 显示文摘	Walenga JM Jeske WP Wood J J	1999	Semin Hematol1999，36，11：	1
15	Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies显示文摘	AHMAD S JESKE WP WALENGA JM	1999	Clin Appl Thromb Hemost1999，5，4：	1
16	Heparin,low-molecular-weight heparins, and heparin pentasaccharide, basic and clinical differentiation 显示文摘	Hoppensteadt D Walenga JM Fareed J	2003	Hematol Oncol Clin North Am2003，17，1：	1
17	显示文摘	Hass S Walenga JM Jeske WP	1999	Semin Thromb Hemost1999，251，：	1
18	Fondaparinux: a synthetic hepar in pentasaccharide as a new antithrombotic agent显示文摘	WALENGA JM JESKE WP SAMAMA MM	2002	Expert Opin Investig Drugs2002，11，3：	1
19	Heparin - induced thrombocytopenia: the role plateletactivation and therapeutic implication 显示文摘	Haas S Walenga JM Jeske UP	1999	Serain Thromb Hemost1999，，：	1
20	Biochemical and pharmacologic inequivalence of low molecular weight heparins 显示文摘	Fareed J Walenga JM Hoppensteadt D	1989	Ann NYAcad Sei1989，556，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示